Alzheimer’s disease (AD) is an irreversible dementia state with characteristic clinical manifestations, including declining cognitive skills and loss of memory, which particularly affects the older population. Despite significant efforts in the field of nano-based drug delivery, there have been few successes achieved in the design of a rational drug therapy. Nanoemulsions (NEs) have potential for the delivery of AD therapeutics owing to their capability for brain drug delivery. Still, there is a long way to go before such therapeutics become a reality in the clinic. In this review, we highlight the preclinical assessment of NEs for AD and discuss the regulatory constraints to their clinical acceptance.

阿尔茨海默病 (AD) 是一种不可逆的痴呆状态，具有特征性临床表现，包括认知技能下降和记忆丧失，尤其影响老年人群。尽管在基于纳米的药物递送领域做出了重大努力，但在设计合理的药物疗法方面取得的成功很少。纳米乳剂 (NEs) 具有递送 AD 治疗药物的潜力，因为它们具有脑药物递送的能力。尽管如此，在这种疗法在临床上成为现实之前还有很长的路要走。在这篇综述中，我们重点介绍了 NE 对 AD 的临床前评估，并讨论了对其临床接受度的监管限制。